Ingalls & Snyder LLC’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$506K Sell
3,964
-2
-0.1% -$250 0.02% 292
2025
Q4
$484K Sell
3,966
-30
-0.8% -$3.44K 0.02% 300
2025
Q3
$400K Sell
3,996
-60
-1% -$5.4K 0.01% 327
2025
Q2
$336K Sell
4,056
-100
-2% -$7.98K 0.01% 352
2025
Q1
$337K Sell
4,156
-215
-5% -$19.2K 0.01% 344
2024
Q4
$394K Sell
4,371
-603
-12% -$58.4K 0.02% 323
2024
Q3
$491K Hold
4,974
0.02% 301
2024
Q2
$461K Sell
4,974
-55
-1% -$4.93K 0.02% 294
2024
Q1
$477K Sell
5,029
-100
-2% -$9.28K 0.02% 294
2023
Q4
$458K Sell
5,129
-835
-14% -$62K 0.02% 293
2023
Q3
$435K Sell
5,964
-555
-9% -$44.3K 0.02% 297
2023
Q2
$542K Sell
6,519
-30
-0.5% -$2.51K 0.03% 283
2023
Q1
$499K Sell
6,549
-500
-7% -$41.5K 0.03% 286
2022
Q4
$585K Sell
7,049
-3,048
-30% -$247K 0.03% 258
2022
Q3
$801K Sell
10,097
-67
-0.7% -$5.65K 0.04% 217
2022
Q2
$755K Sell
10,164
-720
-7% -$54K 0.04% 232
2022
Q1
$978K Sell
10,884
-2,330
-18% -$215K 0.04% 229
2021
Q4
$1.48M Sell
13,214
-50
-0.4% -$6.03K 0.07% 182
2021
Q3
$1.67M Sell
13,264
-473
-3% -$60.9K 0.08% 182
2021
Q2
$1.86M Sell
13,737
-1,723
-11% -$227K 0.08% 174
2021
Q1
$2.1M Sell
15,460
-67
-0.4% -$10K 0.1% 157
2020
Q4
$2.19M Sell
15,527
-1,942
-11% -$249K 0.11% 146
2020
Q3
$1.95M Buy
17,469
+14,969
+599% +$1.68M 0.13% 122
2020
Q2
$280K Buy
+2,500
New +$246K 0.02% 323

Other funds holding XBI

Ingalls & Snyder LLC's XBI Position: Q1 2026 in Review

Ingalls & Snyder LLC reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 0.05% in Q1 2026, selling an estimated $250 and leaving 3,964 shares worth $506K. The position accounts for 0.02% of the portfolio, ranked #292.

Ingalls & Snyder LLC first reported a position in XBI in Q2 2020 and has held it in 24 quarters since. The position peaked at $2.19M in Q4 2020. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

  • Ingalls & Snyder LLC held 3,964 shares of State Street SPDR S&P Biotech ETF worth $506K as of Q1 2026.
  • Ingalls & Snyder LLC sold 2 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $250.
  • State Street SPDR S&P Biotech ETF made up 0.02% of Ingalls & Snyder LLC's portfolio in Q1 2026, its #292 holding.
  • Ingalls & Snyder LLC first reported a position in State Street SPDR S&P Biotech ETF in Q2 2020 and has held it in 24 quarters since.
  • Ingalls & Snyder LLC's State Street SPDR S&P Biotech ETF position peaked at $2.19M in Q4 2020.
  • 813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Ingalls & Snyder LLC's 13F filing for Q1 2026, filed 13 May 2026.